8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 12, 2010

MEDTOX SCIENTIFIC, INC.

(Exact name of registrant as specified in its charter)

Delaware	1-11394	95-3863205
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

402 West County Road D, St. Paul, Minnesota	55112
(Address of principal executive offices)	(Zip Code)

Registrant’s telephone number, including area code: (651) 636-7466

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 7.01.                      Regulation FD Disclosure

On November 12, 2010, MEDTOX Scientific, Inc. announced that it has declared a special one-time dividend of $1.25 per share payable on December 1, 2010 to stockholders of record on November 22, 2010, as described in the press release attached as Exhibit 99.1.

- 2 -

Item 9.01.                      Financial Statements and Exhibits.

(c) Exhibits.

The following exhibit is filed as part of this report:

Exhibit No.	Description
99.1	MEDTOX Scientific, Inc. Press Release, dated November 12, 2010.

- 3 -

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

MEDTOX Scientific, Inc.

Date:  November 12, 2010                                                                    By:       /s/ Richard J. Braun                           

Name:  Richard J. Braun

Title:    Chief Executive Officer

- 4 -

INDEX TO EXHIBITS

Exhibit No.	Description
99.1	MEDTOX Scientific, Inc. Press Release, dated November 12, 2010.

- 5 -

EX-99.1

Exhibit 99.1

MEDTOX Scientific, Inc.

402 West County Road D

St. Paul, MN 55112

Contact: Paula Perry (877) 715-7236

MEDTOX SCIENTIFIC DECLARES

 SPECIAL ONE-TIME DIVIDEND OF $1.25 PER SHARE

ST. PAUL, Minn., November 12, 2010-MEDTOX Scientific, Inc. (Nasdaq:MTOX) today announced that its board of directors approved a special one-time cash dividend of $1.25 per share. The special dividend will be payable on December 1, 2010, to stockholders of record on November 22, 2010.

Cash for the dividend will be provided by cash on hand and borrowing from the Company’s short-term revolving credit facility. The Company currently has no short or long-term debt. A portion of the dividend may be a return of capital (cost basis) and will be nontaxable. That amount cannot be calculated until year-end and will be delineated as such on the form 1099-DIV provided to stockholders. The Company declared the dividend based on its improving performance, cash balances and anticipated ability to generate cash flow from operations, and therefore believes it appropriate to return some capital to stockholders through a one-time cash dividend.

MEDTOX Scientific, Inc., headquartered in St. Paul, Minn., is a provider of high quality specialized laboratory testing services and on-site/point-of-collection testing (POCT) devices. The company also supports customers with complete logistics, data and program management services. MEDTOX is a leader in providing esoteric laboratory testing services to hospitals and laboratories nationwide. This includes both central laboratory and bio-analytical testing for pharmaceutical clinical trials. MEDTOX develops and manufactures diagnostic devices for quick and economical on-site/point-of-collection analysis for drugs-of-abuse, therapeutic drugs and biological and agricultural toxins and provides employment drug screening and occupational health testing. For more information see www.m edtox.com.

Note: Forward looking statements contained in this press release are made under the Private Securities Litigation Reform Act of 1995.  Forward-looking statements, including those relating to the tax treatment of the dividend, the Company’s improving performance, cash balances and anticipated ability to generate cash flow from operations, are subject to risks, uncertainties and other factors that could cause actual results to differ materially from those stated in such statements.  Actual results may differ due to a number of factors including interpretations of tax laws and regulations, a change in the employment pattern of client companies, the ability of MEDTOX to acquire new business and retain existing business and manage its cash, and changes in the competitive environment.  F urther discussions of factors that may cause such results to differ are identified in the Company's 2009 Annual Report on Form 10-K and incorporated herein by reference.   You should take such factors into account when making investment decisions and are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date on which they are made.  We undertake no obligation to update any forward-looking statements.